

STUDY	DESCRIPTION	cases	OTA 61C	OTA 61B	YB APC	YB LC
Vaidya et al 2012 (28)	CASE SERIES	91	41	50	30	33
Gardner et al 2012 (29)	CASE SERIES	24	24			
Merriman et al 2012 (30)	CASE SERIES	13				
Muller et al 2013 (31)	CASE SERIES	36	36			
Owen et al 2013 (32)	CASE REPORT	1	1		1	
Scheyerer et 2014 (33)	CASE SERIES	4	2	2	1	2
Hesse et al 2014 (34)	CASE SERIES	8	6	2	1	3
Hoskins et al 2016 (36)	PROSPECTIVE CAS	21	3	19	3	18
Zhang et al 2016 (37)	CASE SERIES	28	6	22	2	19
Gang et al 2016 (38)	CASE SERIES	12	3	9	4	5
Zhaohui et al 2016 (39)	CASE SERIES	12	8	4		
Wu et al 2017 (41)	CASE SERIES	23	5	18		
Fang et al 2017 (42)	CASE SERIES	29	15	14		
Smith et al 2017 (43)	CASE REPORT	1	1		1	
Bi et al 2017 (44)	CASE CONTROL SE	21		21		
Vaidya et al 2017 (45)	CASE SERIES	83	39	44	20	39
Mantu et al 2017 (46)	CASE REPORT	1		1	1	
wang et al 2017 (47)	CASE CONTROL SE	26		26		
Shetty et al 2017 (48)	CASE SERIES	15	13	2		
Dahill et al 2017 (49)	CASE SERIES	47				
		496	203	234		

YB VS	YB CM	no union	outcome scores	AVG FU	LFCN palsy	HO
20	7	0		15 mo; range, 6-427	temporary	32
		0		12 mo	2 fully resolved	6
		0		29 weeks (5-76 weeks)		
		1	German Pelvic Scc	54 mo	6 persistent	9
				12 mo		
	1	0		not reported	0	0
2	1			<6 mo		
		0		342 days (182-537)	12 improved	9
6		0		8.7 mo (6-12)	12 all recovered	
3		0		6 mo(3-13)	0	0
		0		7.5 mo (6-12)	4 temporary	0
		0	majeed	15 mo (range, 13-3)	3 resolved	8
				7.2 mo	14 persistent	
		0	majeed	16.6 mo (range 12-3)	temporary	
18	6	0	majeed	33.29 mo (range 12.15- 80.33)		56
		0	majeed	6 mo	2 temporary	0
		0	majeed	34.9 mo (31-42)	1 temporary	
		1		12 mo	16 persistent	

early Reop	Infection
6	3 of 91
0	1
0	1 of 13
0	2 of 36
1	
0	0/4
6	
2	3 of 21
0	0
0	0
1	0
1	0
5	1 of 29
1	
1	0
6	3 of 83
1	
0	0
0	1 of 15
4	1 of 47